We report the results of unrelated cord blood transplantation (CBT) for 13 adult patients with advanced MDS. The median age was 40 years, the median weight was 51 kg, and the median number of infused nucleated cells was 2.43 x 10 7 /kg.
Introduction
The prognosis of advanced myelodysplastic syndrome (MDS) is poor. Although some patients with advanced MDS achieve remission with standard intensive chemotherapy, the duration is usually limited. 1 Therefore, allogeneic stem cell transplantation is considered to be the only curative therapy for advanced MDS patients. Recently, alternative donor sources other than human leukocyte antigen (HLA)-identical siblings have been used as allogeneic stem cell sources. [2] [3] [4] We have previously reported the results of a group of seven adult patients with MDS-related secondary acute myeloid leukemia (AML) who received unrelated cord blood transplantation (CBT). 5 Here, we report our clinical results for a larger group of thirteen adult patients with advanced MDS treated with unrelated CBT.
Study design
Between August 1998 and June 2002, thirteen adult patients with advanced MDS were treated with unrelated CBT at The Institute of Medical Science, University of Tokyo. MDS was defined by the French-American-British (FAB) Cooperative Group criteria. 6 MDS-related secondary AML was defined as AML which developed during the follow-up period of MDS. Analyses of data were performed on December 1, 2002. All patients received three to four fractionated 12 Gy total body irradiation (TBI) on days -9, -8, and -7 or days -9 and -8. Cytosine arabinoside (Ara-C) was administered intravenously (i.v.) over 2 h at a dose of 3 g/m 2 every 12 h on days -6 and -5 or days -5 and -4 (total dose 12 g/m 2 ).
Recombinant human granulocyte colony-stimulating factor (G-CSF) was administered by continuous infusion at a dose of 5 ug/kg/day. Infusion of G-CSF was started 12 h before the first dose of Ara-C and stopped at the completion of the last dose. Cyclophosphamide (CY) was administered i.v. over 2 h at a dose of 60 mg/kg once daily on days -4 and -3 or days -3 and -2 (total dose 120 mg/kg).
Two days or 3 days after the completion of conditioning, patients received a cord MDS-related secondary AML included in our previous study were also included (case1-7). 5 No patients had a related or unrelated bone marrow donor available at the time of transplantation. Written informed consent for treatment was obtained from all patients. The probability of disease-free survival (DFS) was estimated by the Kaplan-Meier method.
Results and discussion
The characteristics of the thirteen patients and cord blood units are shown in Table   1 . Among the thirteen patients, eight did not receive any induction therapy before transplantation. Among the other five patients who received induction therapy, four could not achieve complete remission. Therefore, all but one received CBT as an up-front treatment not a post remission consolidation. Among the patients the median age was 40 years (range, 20-51 years), the median weight was 51 kg Although the patients required early transplantation, none of our patients had any related or unrelated bone marrow donors. Therefore, unrelated cord blood, which has the advantage of rapid availability, was used as an alternative stem cell source.
The long-term DFS rate for advanced MDS patients receiving allogeneic stem cell transplantation is approximately 30% 3, 11, 12 and high relapse rates may result in a unfavorable rate of DFS. The relatively higher incidence of chronic GVHD and the use of G-CSF-combined preparative regimen, which was capable of
reducing the post-transplant relapse rate in refractory myeloid malignancies, 13, 14 may be associated with a high DFS rate (76.2% at 2 years) in our study. Also, all patients in our study received more than 2 x 10 7 nucleated cells per weight, 
